Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations

被引:33
作者
Vermeulen, F. [1 ]
Le Camus, C. [2 ]
Davies, J. C. [3 ,4 ,5 ]
Bilton, D. [3 ,6 ]
Milenkovic, D. [6 ]
De Boeck, K. [1 ]
机构
[1] Univ Hosp Leuven, Cyst Fibrosis Reference Ctr, Herestr 49, B-3000 Louvain, Belgium
[2] Vertex Pharmaceut Inc, Cambridge, MA USA
[3] Imperial Coll London, London, England
[4] Royal Brompton & Harefield Natl Hlth Serv Fdn Tru, Paediat Resp Med, London, England
[5] Royal Brompton & Harefield Natl Hlth Serv Fdn Tru, Dept Cyst Fibrosis, London, England
[6] London Sch Hyg & Trop Med, London, England
关键词
Sweat chloride; Cystic fibrosis; G551D; Endpoint; Variability; CFTR POTENTIATOR; IVACAFTOR; TRIAL;
D O I
10.1016/j.jcf.2016.02.015
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: Sweat chloride concentration, a biomarker of CFTR function, is an appropriate outcome parameter in clinical trials aimed at correcting the basic CF defect. Although there is consensus on a cut-off value to diagnose CF, we have only limited information on the within subject variability of sweat chloride over time. Such information would be useful for sample size calculations in clinical trials. Therefore, we retrospectively analyzed repeated sweat chloride values obtained in patients with G551D mutation(s) assigned to placebo in an ivacaftor interventional trial. Methods: In subjects with G551D at least 12 years of age, a pilocarpine sweat test using Macroduct collector was taken on both arms at 8 time points over 48 weeks. We explored 1062 pilocarpine sweat test values obtained in 78 placebo patients of the VX08-770-102 trial. Results: Mean overall sweat chloride value (all patients, all tests, n = 1062) was 100.8 mmol/L (SD 12.7 mmol/L). Using a multilevel mixed model, the between-subject standard deviation (SD) for sweat chloride was 8.9 mmol/L (95% CI 7.4-10.6) and within-subject SD was 8.1 mmol/L (95% CI 7.5-8.7). Limits of repeatability for repeat measurements were -19.7 to +21.6 mmol/L using values from one arm, and -13.3 to 11.8 mmol/L using mean of values obtained at 4 test occasions. Sample size calculations showed that the minimal treatment effect on sweat chloride concentration that can be demonstrated for a group of 5 patients is around 15 mmol/L, using a cross-over design and combinations of 4 tests for each phase of the trial. Conclusion: Although the sweat test is considered a robust measure, sweat chloride measurements in patients with CF and a G551D mutation had an inherent biological variability that is higher than commonly considered. Further analyses of placebo group data are crucial to learn more about the natural variability of this outcome parameter. (C) 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:36 / 40
页数:5
相关论文
共 12 条
[1]   Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data [J].
Accurso, Frank J. ;
Van Goor, Fredrick ;
Zha, Jiuhong ;
Stone, Anne J. ;
Dong, Qunming ;
Ordonez, Claudia L. ;
Rowe, Steven M. ;
Clancy, John Paul ;
Konstan, Michael W. ;
Hoch, Heather E. ;
Heltshe, Sonya L. ;
Ramsey, Bonnie W. ;
Campbell, Preston W. ;
Ashlock, Melissa A. .
JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (02) :139-147
[2]   Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation [J].
Accurso, Frank J. ;
Rowe, Steven M. ;
Clancy, J. P. ;
Boyle, Michael P. ;
Dunitz, Jordan M. ;
Durie, Peter R. ;
Sagel, Scott D. ;
Hornick, Douglas B. ;
Konstan, Michael W. ;
Donaldson, Scott H. ;
Moss, Richard B. ;
Pilewski, Joseph M. ;
Rubenstein, Ronald C. ;
Uluer, Ahmet Z. ;
Aitken, Moira L. ;
Freedman, Steven D. ;
Rose, Lynn M. ;
Mayer-Hamblett, Nicole ;
Dong, Qunming ;
Zha, Jiuhong ;
Stone, Anne J. ;
Olson, Eric R. ;
Ordonez, Claudia L. ;
Campbell, Preston W. ;
Ashlock, Melissa A. ;
Ramsey, Bonnie W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (21) :1991-2003
[3]   Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis [J].
Ahrens, RC ;
Standaert, TA ;
Launspach, J ;
Han, SH ;
Teresi, ME ;
Aitken, ML ;
Kelley, TJ ;
Hilliard, KA ;
Milgram, LJH ;
Konstan, MW ;
Weatherly, MR ;
McCarty, NA .
PEDIATRIC PULMONOLOGY, 2002, 33 (02) :142-150
[4]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[5]   A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial [J].
Boyle, Michael P. ;
Bell, Scott C. ;
Konstan, Michael W. ;
McColley, Susanna A. ;
Rowe, Steven M. ;
Rietschel, Ernst ;
Huang, Xiaohong ;
Waltz, David ;
Patel, Naimish R. ;
Rodman, David .
LANCET RESPIRATORY MEDICINE, 2014, 2 (07) :527-538
[6]   Cystic fibrosis: terminology and diagnostic algorithms [J].
De Boeck, K. ;
Wilschanski, M. ;
Castellani, C. ;
Taylor, C. ;
Cuppens, H. ;
Dodge, J. ;
Sinaasappel, M. .
THORAX, 2006, 61 (07) :627-635
[7]   Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation [J].
De Boeck, Kris ;
Munck, Anne ;
Walker, Seth ;
Faro, Albert ;
Hiatt, Peter ;
Gilmartin, Geoffrey ;
Higgins, Mark .
JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (06) :674-680
[8]   Has My Patient Responded? Interpreting Clinical Measurements Such As the 6-Minute-Walk Test [J].
Dolmage, Thomas E. ;
Hill, Kylie ;
Evans, Rachael A. ;
Goldstein, Roger S. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (06) :642-646
[9]  
GIBSON LE, 1959, PEDIATRICS, V23, P545
[10]   CLINICAL-EVALUATION OF THE MACRODUCT SWEAT COLLECTION SYSTEM AND CONDUCTIVITY ANALYZER IN THE DIAGNOSIS OF CYSTIC-FIBROSIS [J].
HAMMOND, KB ;
TURCIOS, NL ;
GIBSON, LE .
JOURNAL OF PEDIATRICS, 1994, 124 (02) :255-260